Atıf İçin Kopyala
Düzgüneş N., Piskorz J., Skupin-Mrugalska P., Yıldırım M., Sessevmez M., Cheung J.
ORAL, cilt.3, sa.3, ss.276-294, 2023 (Hakemli Dergi)
-
Yayın Türü:
Makale / Derleme
-
Cilt numarası:
3
Sayı:
3
-
Basım Tarihi:
2023
-
Doi Numarası:
10.3390/oral3030023
-
Dergi Adı:
ORAL
-
Sayfa Sayıları:
ss.276-294
-
İstanbul Üniversitesi Adresli:
Evet
Özet
Photodynamic therapy facilitates the selective destruction of cancer tissue by utilizing a photosensitizer drug, the light near the absorbance wavelength of the drug, and oxygen. Methylene Blue, 5-aminolevulinic acid (the precursor of the photosensitizer, protoporphyrin IX), porphyrin, Foscan, Chlorin e6, and HPPH have been used successfully as photosensitizers in the treatment of oral verrucous hyperplasia, oral leukoplakia, oral lichen planus, and head and neck squamous cell carcinoma. “Theranostic” liposomes can deliver a contrast agent for magnetic resonance imaging and a photosensitizer for the image-guided photodynamic therapy of head and neck cancer. Liposomes incorporating photosensitizers can be targeted to cell surface markers overexpressed on cancer cells. Novel porphyrinoids have been developed in our laboratories that are highly effective as photosensitizers. Tribenzoporphyrazines encapsulated in cationic liposomes have produced IC50 values up to 50 times lower compared to the free photosensitizers. It is anticipated that targeting these drugs to cancer stem cells, using upconversion nanoparticles for the near-infrared irradiation of tumors to activate the photosensitizers, and overcoming tumor hypoxia will enhance the efficacy of photodynamic therapy of tumors accessible to light sources.